JC
Highly rated in
35
conditions
Highly rated in
35
conditions
Check Dr. Jason C. Comer's experience treating your condition:
About Dr. Jason C. Comer

Jason Comer is a Hematologist Oncology expert in Bellevue, Washington. Comer has been practicing medicine for over 22 years and is highly rated in 35 conditions, according to our data. His top areas of expertise are Familial Colorectal Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Ovarian Carcinosarcoma. He is licensed to treat patients in Washington. Comer is currently accepting new patients.

His participating in 7 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Jason C. Comer it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Jason C. Comer accepts the following insurance:

  •  Ambetter
  •  Premera

Call to see if your plan is accepted.
Locations
1135 116th Ave Ne, Suite 250, Bellevue, WA 98004
Background & Education
Graduate Institution
Other, 2000
Specialties
Hematology Oncology
Licenses
Internal Medicine in WA
Hospital Affiliations
Overlake Medical Center & Clinics
Seattle Cancer Care Alliance
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
View 2 Less Clinical Trial -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors